-
COPsync Inc (NASDAQ: COYN) shares tumbled 39.4
percent to $0.624 after the company reported a $1.15 million registered direct offering.
-
Ruby Tuesday, Inc. (NYSE: RT) shares dropped 21.5
percent to $2.77 after the company posted a wider quarterly loss. Ruby Tuesday reported Q2 adjusted loss of $0.18 per share on
revenue of $214.7 million.
-
Stein Mart, Inc. (NASDAQ: SMRT) shares declined
14.5 percent to $4.50. Stein Mart reported a 4.8 percent drop in its comparable store sales for the nine-week period ended
December 31, 2016.
-
Turtle Beach Corp (NASDAQ: HEAR) shares fell 12.3
percent to $1.50.
-
Dataram Corp (NASDAQ: DRAM) dropped 12 percent to
$1.46. Dataram shares have dropped 20.95 percent over the past 52 weeks, while the S&P 500 index has gained 14.01 percent
in the same period.
-
ICU Medical, Incorporated (NASDAQ: ICUI) shares
fell 11.8 percent to $130.00 after the company issued an update on Hospira Infusion Systems transaction. The company expects
the deal to close in February 2017.
-
Avinger Inc (NASDAQ: AVGR) dropped 8 percent to
$3.59 after the company reported preliminary Q4 results.
-
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) fell
7.1 percent to $354.00. Amgen won a court ruling for a ban on Regeneron’s sales of Praluent cholestrol drug.
-
Orexigen Therapeutics, Inc. (NASDAQ: OREX) fell
6.9 percent to $3.52 after climbing 11.18 percent on Thursday.
-
Mercer International Inc. (NASDAQ: MERC) declined
6 percent to $10.77. RBC Capital downgraded Mercer from Outperform to Sector Perform
-
Pandora Media Inc (NYSE: P) shares fell 5.1 percent to
$12.35.
-
AZZ Inc (NYSE: AZZ) shares fell 5 percent to $61.40
after the company announced weak Q3 results.
-
G-III Apparel Group, Ltd. (NASDAQ: GIII) shares
fell 3 percent to $27.80 after the company lowered its guidance for FY17.
-
GoPro Inc (NASDAQ: GPRO) shares fell around 3
percent to $9.07. Longbow Research downgraded GoPro from Neutral to Underperform.
-
Wendys Co (NASDAQ: WEN) declined 2.6 percent to
$13.28. Longbow Research downgraded Wendys from Buy to Neutral.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.